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Abstract: Background 
To evaluate inter-multidisciplinary team agreement for the diagnosis of 
diffuse parenchymal lung disease (DPLD). 
 
Methods 
Seven multidisciplinary meetings (MDTMs) consisting of at least one 
clinician, radiologist and pathologist, from 7 different countries 
evaluated 70 cases of diffuse lung disease in a two-stage process. First, 
the clinician, radiologist and pathologist (when lung biopsy was 
performed) evaluated each case and chose likelihoods (censored at 5% and 
summing to 100% in each case) for each of their differential diagnoses, 
without inter-disciplinary consultation. A full MDTM with review of all 
clinical, radiologic and pathologic data followed this. Interobserver 
agreement and inter-MDTM agreement for diagnosis was calculated using  
Cohen's kappa coefficient or weighted kappa coefficient where 
appropriate.  
 
Findings   
Inter-MDTM agreement for first choice diagnoses was acceptable (κ = 
0.50). Idiopathic pulmonary fibrosis made up 18% of all MDTM first choice 
diagnoses. Diagnostic likelihoods for MDTM differential diagnoses were 
converted to a 5-point scale (0 = condition not included in the 
differential diagnosis, 1 = low probability (5-25%), 2 = intermediate 
probability (30-65%), 3 = high probability (70-95%), and 4 = 
pathognomonic (100%)). Inter-MDTM agreement on diagnostic likelihoods was 
good for idiopathic pulmonary fibrosis (IPF) (κw = 0.71) and connective 
tissue disease related interstitial lung disease (CTD-ILD) (κw = 0.73), 
only moderate for non-specific interstitial pneumonia (NSIP) (κw = 0.42) 
and poor for hypersensitivity pneumonitis (HP) (κw = 0.29). MDTMs, 
clinicians and radiologists respectively gave high confidence diagnoses 
of IPF (>65% likelihood) in 77.3%, 64.6% and 66.3% of cases. The 
prognostic significance of a first choice diagnosis of IPF versus not IPF 
was evaluated for MDTMs, clinicians and radiologists. Greater prognostic 
significance was demonstrated for an MDTM diagnosis of IPF as compared to 
individual clinician's diagnosis of IPF in 5/7 MDTMs, radiologist's 
diagnosis of IPF in 4/7 MDTMs.  
 
Interpretation 
Agreement between MDTMs for diagnosis in diffuse lung disease is 
acceptable and good for a diagnosis of IPF. This is validated by the 
greater prognostic significance of an IPF diagnosis made by MDTMs as 
compared to individual clinicians or radiologists. Furthermore, MDTMs 
made the diagnosis of IPF with higher confidence and more frequently than 
clinicians or radiologists. MDTM agreement for diagnosis of NSIP and 
hypersensitivity pneumonitis is poor, indicating a need for international 
consensus on diagnostic criteria for these diseases.  
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Abstract 
 
Background 
To evaluate inter-multidisciplinary team agreement for the diagnosis of diffuse 
parenchymal lung disease (DPLD). 
 
Methods 
Seven multidisciplinary meetings (MDTMs) consisting of at least one clinician, 
radiologist and pathologist, from 7 different countries evaluated 70 cases of diffuse 
lung disease in a two-stage process. First, the clinician, radiologist and pathologist 
(when lung biopsy was performed) evaluated each case and chose likelihoods 
(censored at 5% and summing to 100% in each case) for each of their differential 
diagnoses, without inter-disciplinary consultation. A full MDTM with review of all 
clinical, radiologic and pathologic data followed this. Interobserver agreement and 
inter-MDTM agreement for diagnosis was calculated using Cohen’s kappa coefficient 
or weighted kappa coefficient where appropriate.  
 
Findings   
Inter-MDTM agreement for first choice diagnoses was acceptable (κ = 0·50). 
Idiopathic pulmonary fibrosis made up 18% of all MDTM first choice diagnoses. 
Diagnostic likelihoods for MDTM differential diagnoses were converted to a 5-point 
scale (0 = condition not included in the differential diagnosis, 1 = low probability (5–
25%), 2 = intermediate probability (30–65%), 3 = high probability (70–95%), and 4 = 
pathognomonic (100%)). Inter-MDTM agreement on diagnostic likelihoods was good 
for idiopathic pulmonary fibrosis (IPF) (κw = 0·71) and connective tissue disease 
related interstitial lung disease (CTD-ILD) (κw = 0·73), only moderate for non-specific 
interstitial pneumonia (NSIP) (κw = 0·42) and poor for hypersensitivity pneumonitis 
(HP) (κw = 0·29). MDTMs, clinicians and radiologists respectively gave high 
confidence diagnoses of IPF (>65% likelihood) in 77·3%, 64·6% and 66·3% of cases. 
The prognostic significance of a first choice diagnosis of IPF versus not IPF was 
evaluated for MDTMs, clinicians and radiologists. Greater prognostic separation was 
demonstrated for an MDTM diagnosis of IPF as compared to individual clinician’s 
diagnosis of IPF in 5/7 MDTMs, radiologist’s diagnosis of IPF in 4/7 MDTMs.  
 
Interpretation 
Agreement between MDTMs for diagnosis in diffuse lung disease is acceptable and 
good for a diagnosis of IPF. This is validated by the greater prognostic separation of 
an IPF diagnosis made by MDTMs as compared to individual clinicians or radiologists. 
Furthermore, MDTMs made the diagnosis of IPF with higher confidence and more 
frequently than clinicians or radiologists. MDTM agreement for diagnosis of NSIP and 
hypersensitivity pneumonitis is poor, indicating a need for international consensus on 
diagnostic criteria for these diseases.  
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Introduction 
Diffuse parenchymal lung disease (DPLD) represents a diverse and challenging 
group of pulmonary disorders with varied prognoses and different management 
options. A consistent diagnostic approach to these diseases is essential if clinical trial 
data is to be reliably applied to individual patients. With the recent licensing of two 
new anti-fibrotic idiopathic pulmonary fibrosis (IPF) therapies, accurate and consistent 
diagnosis of IPF is of particular importance if clinical benefit is to be achieved1,2. In 
2002, a joint statement by the American Thoracic Society (ATS) and the European 
Respiratory Society (ERS) on the classification of the idiopathic interstitial 
pneumonias (IIPs) advocated a multidisciplinary diagnostic approach involving 
integration of clinical, radiologic and, when lung biopsy material is available, 
pathologic data3. This approach has been emphasised by several studies in recent 
years and was re-stated in the 2013 ATS/ERS update on the IIPs4-8.  Although this 
recommendation specifically applies to IIP, the multidisciplinary approach has been 
widely adopted as the diagnostic gold standard for DPLD in general5,7. Several 
studies have evaluated interobserver agreement for diagnosis in the setting of DPLD 
5-7,9, but most predate the 2013 ATS/ERS IIP classification update, the 2011 
ATS/ERS/JRS/ALAT statement on the diagnosis and management of IPF and the 
availability of novel anti-fibrotic IPF drugs, all of which may impact decisions on 
diagnosis1,2,4,10. Furthermore, many of these studies focus on individual observers 
rather than agreement between multidisciplinary teams (MDTs) 5-7,9,11. In this study, 
we evaluated the level of inter-MDTM diagnostic agreement between seven 
international centres. 
 
 
Methods 
Patient and Multidisciplinary team selection 
For the retrospective examination of clinically indicated data, the institutional ethics 
review board waived informed patient consent. Patients selected for this study 
represented consecutive patients presenting to the interstitial lung disease unit of the 
Royal Brompton & Harefield NHS Foundation Trust and requiring MDTM 
characterisation, between March 1st 2010 and August 31st 2010. Only patients who 
had all their clinical investigations (serology, HRCT and when required, surgical lung 
biopsy) performed at the host institution were included. A total of 7 MDTMs from 7 
different countries (Denmark, France, Italy, Japan, Netherlands, Portugal and the 
United Kingdom), each with specialist expertise in the diagnosis and management of 
DPLD, were invited to participate in the study.  The only prerequisite for participation 
was that each MDT had a regular multidisciplinary meeting for DPLD in place with 
consistent attendance by at least one clinician, radiologist and pathologist. 
 
Evaluation of cases 
The evaluation of each of case took place in two stages· 
  
1. First, clinicians, radiologists and pathologists were required to review the cases 
independently without inter-specialty consultation. Clinicians had access to all 
the presenting clinical information (age, gender, smoking history, history of 
established connective tissue disease (CTD), symptoms including symptoms 
suggestive of a CTD, autoantibody profile, exposure history, medications at 
presentation, bronchoalveolar lavage result if performed, and ACE level if 
performed), pulmonary function tests and HRCT (without access to the original 
HRCT report). Radiologists and pathologists had access only to the age, 
gender and smoking history for the patient, and the HRCT (radiologist) or 
digitized surgical lung biopsy slides (pathologist) at presentation. Specifically, 
pathologists had access to all the pathology data that was available in the form 
of digitized slides (in .svs format) and were viewed using Aperio ImageScope 
12·3 viewing software. This digital viewing application has all the imaging 
functionality normally available to pathologists in routine clinical practice and is 
used by the host institution to evaluate cases referred from outside institutions 
for opinions.  
For each patient, observers were required to select up to 5 differential 
diagnoses and provide a diagnostic likelihood (censored at 5% and summing 
to 100% in each case) from a drop-down menu of diffuse lung diseases 
(Appendix, Table A1). The only stipulation was that diagnoses were 
considered in the context of the current ATS/ERS classification and 
terminology for the IIPs4· 
 
2. Second, the clinician, radiologist and pathologist convened as an MDT and 
reviewed the cases together, again providing up to 5 diagnoses with diagnostic 
likelihoods (also censored at 5% and summing to 100% in each case). All the 
clinical information supplied in the first stage, pulmonary function tests and 
HRCT at presentation as well as digitized surgical lung biopsy slides were 
available to the MDT for review.   
 
 
 
 Outcome 
As a means of validating the diagnosis made by MDTM versus individual specialists, 
the mortality of each groups’ diagnosis of IPF was compared. This was achieved by 
separating the entire cohort into a binary IPF diagnosis category (IPF and not IPF) for 
each MDTM, clinician and radiologist based upon assigned diagnoses. The survival 
period for each patient was calculated from the date of referral to the host institution 
to the minimum of date of death, date the patient was last known to be alive or 1st 
June 2015 (end of the study period). Vital status for each patient on the 1st June 2015 
was obtained by evaluating his or her electronic patient record.  
 
Statistical analysis 
Data are given as means with standard deviations (SD), medians with interquartile 
range (IQR) or as number of patients and percentage where appropriate. Statistical 
analyses were performed using STATA (version 12, StataCorp, College Station, 
Texas).  
Cohen’s kappa coefficient (κ) was used to evaluate interobserver and inter-
MDTM agreement for diagnosis. Cohen’s weighted kappa coefficient (κw) was used 
to evaluate interobserver agreement and inter-MDTM agreement for an estimation of 
the probability of each diagnosis. In order to do this, the percentage diagnostic 
likelihood given for each diagnosis was converted to a 5 point scale (0–4), 
representing clinically useful probabilities: 0 = condition not included in the differential 
diagnosis, 1 = low probability (5–25%), 2 = intermediate probability (30–65%), 3 = 
high probability (70–95%), and 4 = pathognomonic (100%). For example, if the 
differential diagnoses given by an MDT were IPF (65% diagnostic likelihood), NSIP 
(25% diagnostic likelihood) and hypersensitivity pneumonitis (10% diagnostic 
likelihood), the probability grades for IPF, NSIP and hypersensitivity pneumonitis for 
this case would be 2, 1 and 1 respectively. Weighted kappa values were calculated 
between paired observers (for statements of interobserver agreement), and between 
paired MDTs (for statements of inter-MDTM agreement) and expressed as median 
values with interquartile ranges for all unique combinations of pairs (21 for 7 
observers or 7 MDTs). Weighting the Kappa coefficient allowed the degree of 
disagreement to be quantified by assigning greater emphasis to large differences 
between scores. Weighted kappa coefficients were categorized as follows: poor (0 < 
κw ≤ 0·20), fair (0·20 < κw ≤ 0·40), moderate (0·40 < κw ≤ 0·60), good (0·60 < κw ≤ 
0·80) and excellent (0·80 < κw ≤ 1·00). This approach has been used in previous 
investigations of interobserver agreement for diagnosis in diffuse lung diseases9,11· 
In addition to the above, in each case the first choice diagnosis was 
considered “low confidence” (diagnostic likelihood <70%), or “high confidence” (70% 
or greater diagnostic likelihood). These categories were based on the diagnostic 
likelihood categories used to assess the clinical probability of pulmonary embolism in 
the PIOPED study12. 
Univariate Cox regression analysis was used to identify associations between 
mortality and MDTM, clinician and radiologist diagnoses in terms of IPF versus “not 
IPF”. Reported hazards ratios are for diagnosis of IPF versus “not IPF”.  The 
assumptions of proportional hazards were tested by 1) visual inspection the log-log 
plot of survival, 2) comparison of the Kaplan-Meier observed survival curves with the 
Cox predicted curves for the same variable and 3) graphical and formal analysis of 
Schoenfeld residuals (analysis not shown). Results are reported as hazard ratios, p-
values and 95% confidence intervals and graphically as Kaplan-Meier survival curves. 
 Role of the funding source: 
The sponsors of the study did not have any role in the design, data collection, 
analysis and interpretation, nor in the writing of the report. The corresponding author 
had full access to all of the data and the final responsibility to submit for publication.
   
Results 
 
Patient population 
A total of 113 consecutive new referrals who required local MDTM characterisation 
were identified from the clinical database between March 1st 2010 and August 31st 
2010. Of these, 43/113 (38·1%) were excluded on the basis that a) their initial work-
up HRCT scan had been performed at the referring institution (n=29), b) their lung 
function had been performed at the referring institution (n=4), or c) surgical lung 
biopsy had been performed by the referring institution (n=10), (Table 1 and Appendix, 
Figure A1). The remaining 70 cases made up the final study population. Basic patient 
demographics are shown in the Appendix, Table A2. Of note, thirteen (19%) had an 
established diagnosis of a connective tissue disease at the time of presentation to the 
host institution and 22/70 (34·1%) underwent surgical lung biopsy at the host 
institution. In cases where surgical lung biopsy was not performed (48/70), a 
confident diagnosis had been made without the need for surgical lung biopsy material. 
Vital status was known for all patients at the end of the study period. These 70 
patients resulted in the assignment of 490 first choice MDTM diagnoses (70 patients 
evaluated by 7 MDTMs). First choice diagnoses are shown in Table 2. The NSIP/OP 
overlap ILD category was combined with the NSIP category and diagnosis categories 
whose frequency was less that 10% of the total number of first choice diagnoses were 
combined into an ‘others’ diagnosis category. The final diagnosis categories were 
then as follows: CTD related ILD (n=146/490, 27·8%), IPF (n=88/490, 18·0%), 
idiopathic NSIP (n=50/490, 10·2%), hypersensitivity pneumonitis (n=46/490, 9·4%) 
and others (n=160/490, 32·7%). Subsequent analyses focused on these four primary 
diagnosis categories.  
 
 
 
Inter-multidisciplinary team and inter-observer agreement for first choice diagnosis 
Inter-MDTM agreement and interobserver agreement (for clinicians, radiologists and 
pathologists) for first choice diagnosis is shown in Table 3. Overall inter-MDTM 
agreement for first choice diagnosis was moderate (κ = 0·50). Inter-MDTM agreement 
for a first choice diagnosis of IPF was good (κ = 0·60), for a first choice diagnosis of 
CTD related ILD also good (κ = 0·64), but poor for first choice diagnoses of idiopathic 
NSIP (κ = 0·25) and hypersensitivity pneumonitis (κ = 0·24). On subgroup analysis in 
patients in whom lung biopsy was not performed (n=48/70, 68·6%), overall inter-
MDTM agreement for diagnosis was greater (κ = 0·57) with inter-MDTM agreement 
for first choice diagnoses of IPF, CTD related ILD and hypersensitivity pneumonitis 
also greater. Overall inter-observer agreement among clinicians for first choice 
diagnosis was moderate (κ = 0·45) and fair between radiologists (κ = 0·33) and 
pathologists (κ = 0·31) (Table 3.).  
 
 
 
Inter-multidisciplinary team and inter-observer agreement for diagnosis probabilities  
There was fair to good inter-MDTM agreement on the estimation of diagnostic 
likelihood of the 4 most prevalent diagnoses as shown in Table 4. In particular, inter-
MDTM agreement on the diagnostic likelihood of IPF was good (κw= 0·71, IQR 0·64-
0·77), and good for CTD related ILD (κw= 0·73, IQR 0·68-0·78) but moderate for 
idiopathic NSIP (κw = 0·41 IQR 0·37-0·49) and fair for hypersensitivity pneumonitis 
(κw = 0·29 IQR 0·24-0·40). Subgroup analysis of inter-MDTM agreement on the 
estimation of diagnostic likelihood of IPF in patients without lung biopsy was good (κw 
= 0·78 IQR 0·74-0·83). 
Agreement between clinicians on the probability of a diagnosis of IPF or CTD-
related ILD was superior to agreement on the probability of a diagnosis of idiopathic 
NSIP or hypersensitivity pneumonitis. Agreement between radiologists or pathologists 
on the probability of a diagnosis of IPF was superior to agreement on the probability 
of a diagnosis of CTD-related ILD, idiopathic NSIP or hypersensitivity pneumonitis.  
 
Subgroup analysis of inter-MDTM agreement in patients without an established 
diagnosis of a connective tissue disease. 
At the time of patient selection, 13/70 (18·6%) patients had an established diagnosis 
of a CTD (systemic sclerosis = 7, rheumatoid arthritis = 3, Sjögren’s syndrome = 2, 
mixed connective tissue disease = 1). In order to investigate if high agreement in 
these 13 cases caused a spurious increase in agreement on non-CTD diagnoses and 
in particular, impacting agreement on a diagnosis of IPF, a subgroup analysis was 
performed in the remainder of the cohort (n=57/70, 81·4%). On this analysis, although 
inter-MDTM agreement for a first choice diagnosis of CTD related ILD decreased (κ = 
0.42), no significant change in inter-MDTM agreement was observed for a first choice 
diagnosis of IPF (κ = 0·58), idiopathic NSIP (κ = 0·24) or hypersensitivity pneumonitis 
(k = 0·23) (Appendix, Table A2). 
 
Diagnostic confidence for first choice diagnoses  
A total of 347/490 (70·1%) first choice MDT diagnoses were made with high 
confidence (diagnostic likelihood 70–95% = high confidence, 100% = pathognomonic). 
The median prevalence of first choice MDT diagnoses made with high confidence 
was 67·1% (IQR 54·3-88·8). The median prevalence of first choice diagnoses made 
with high confidence by clinicians, radiologists or pathologists was 58·9% (IQR 52·9-
71·4), 68·6% (IQR 35·7-85·7) and 72·7% (IQR 59·1-81·8) respectively (Appendix, 
Table A3). On subgroup analysis in the 48/70 (68·6%) patients who did not undergo 
surgical lung biopsy 237/336 (70·5%) first choice MDT diagnoses were made with 
high confidence. Within this subgroup the median prevalence of first choice 
diagnoses made with high confidence by the MDTs, clinicians or radiologists were 
68·7% (IQR 52·8-87·5), 60·4% (IQR 37·5-75·0) and 66·6% (IQR 39·6-83·3) 
respectively.  
For the diagnosis of IPF, supportive non-significant trends for higher 
confidence diagnoses by MDTMs (68/88, 77·3%) as compared to clinicians (62/96, 
64·6%) or radiologists (57/86, 66·3%) were demonstrated (p = 0·23)· In the 22/70 
(31·4%) cases that underwent surgical lung biopsy (therefore a total of 154 diagnoses 
rendered by 7 pathologists), 15/154 (9·7%) cases were assigned a diagnosis of IPF, 
of which 12/15 (80·0%) were assigned with high confidence.     
   A review of the cases where the pathologists gave a first choice 
diagnosis of IPF (15/154 cases, 154 = 22 cases x 7 pathologists) was performed to 
ascertain if, in cases where surgical lung biopsy was performed and the first choice 
pathologic diagnosis was IPF, the final MDTM diagnosis was usually IPF. In 6/15 
cases, despite the pathologist giving a first choice diagnosis of IPF, the final MDTM 
first choice diagnosis was not IPF. Furthermore, in only 2/15 cases, was IPF not 
already suggested by either the clinician or radiologist in that MDTM (Table A5). 
 
 
 
Evaluation of the prognostic significance of an MDTM diagnosis of IPF  
On univariate Cox regression analysis, the multidisciplinary distinction between IPF 
and other diagnoses demonstrated non-significant trends toward greater prognostic 
separation (as judged by hazard ratio p values)  than the clinician distinction (in 5/7 
groups) or the radiologist distinction (in 4/7 groups) (Table 5). A graphical 
presentation of the KM-survival curves for the categorisation of first-choice diagnosis 
as IPF or not IPF in at least 4/7 MDTMs, 4/7 clinicians and 4/7 radiologists is shown 
in Figure 1. The same analysis for pathologists’ diagnosis of IPF failed to reach 
statistical significance for 5/7 pathologists, probably because of the small subgroup 
size (n=22) and low prevalence of IPF within this subgroup (15/154, pathologists’ first-
choice diagnoses were IPF) (Appendix, Table A4 and A5).   
 
 
 
 
 
 
 
Discussion 
We have demonstrated for the first time, that there is acceptable diagnostic 
agreement between multidisciplinary groups in the setting of diffuse parenchymal lung 
disease and that this agreement is validated by the greater prognostic significance of 
an IPF diagnosis made by multidisciplinary groups as compared to individual 
clinicians and radiologists. Furthermore, MDTMs make the diagnosis of IPF with high 
confidence, more frequently than clinicians or radiologists.  
 Since the publication of the ATS/ERS 2002 consensus statement on the 
classification of the IIPs, multidisciplinary evaluation of DPLD has been widely 
adopted as the diagnostic gold standard3,4. This diagnostic approach has been 
investigated in a limited way in several settings. Flaherty et al. examined the 
formulation of diagnosis in a cohort of diffuse lung diseases against interobserver 
agreement and diagnostic confidence within a single multidisciplinary team 
(consisting of 3 clinicians, 2 radiologists and 2 pathologists) and demonstrated that 
diagnostic agreement between observers improved with successive integration of 
clinical, radiologic and pathologic data5. In a second study, Flaherty et al. expanded 
these findings by demonstrating higher levels of agreement between academic 
physicians, radiologists and pathologists for diagnosis in diffuse lung disease when 
compared with their community counterparts7. Several years later, Thomeer et al. 
demonstrated in a cohort of patients included in an IPF trial, high accuracy for a 
clinical diagnosis of IPF made by 6 respiratory physicians from different European 
centres6. A limitation of these studies is that not all evaluated agreement between 
different MDTs for diagnosis 5, one focuses specifically on the diagnosis of IPF6 and 
all of them predate the most recent 2013 ATS/ERS IIP update4-7,9. The current study 
is the first to evaluate inter-MDTM agreement for diagnosis in diffuse lung disease 
since publication of the 2013 ATS/ERS update on the classification of the IIPs.   
With the recent licensing of two new drugs for treatment of IPF in mild to 
moderate disease, early and accurate diagnosis of IPF is crucial. Our study 
demonstrates that inter-MDTM agreement for the diagnosis of IPF is good, with 
clinicians demonstrating only marginally inferior levels of agreement, as compared to 
MDTMs for this diagnosis. On subgroup analysis in patients without surgical lung 
biopsy, inter-MDTM agreement and interobserver agreement between clinicians for 
the diagnosis of IPF improved and were again, almost equal. As evidence-based 
diagnostic criteria for IPF are now clearly defined and in many IPF patients, are 
relatively easily applied, this near parity of agreement between MDTMs and between 
clinicians is not surprising 4,10. For example, in a patient with classic appearances for 
usual interstitial pneumonia (UIP) on HRCT, a rapidly progressive disease course and 
no identifiable triggers, multidisciplinary discussion is unlikely to alter a clinician’s 
initial impression of IPF. Our findings suggest that formal multidisciplinary input may 
not be necessary in every case of suspected IPF if expert clinical evaluation is 
available, which may be of particular relevance to centres with limited access to 
appropriate radiology or pathology expertise13 .  
A strength of our findings is that the greater agreement on multidisciplinary 
diagnosis is mirrored by the trend toward greater prognostic separation of a 
multidisciplinary distinction between IPF and other diagnoses when compared to the 
clinicians’ or radiologists’ distinction. To demonstrate this, patients were necessarily 
selected from 2010 to allow an analysis of 5-year survival.  An added advantage of 
this approach was that these patients were referred in a pre-antifibrotic drug era, 
therefore mortality differences between IPF and non-IPF patients were not 
confounded by antifibrotic therapy. The fact that trends are present but inconclusive 
may reflect powering limitations but may also indicate that multidisciplinary discussion 
adds prognostic value in the sub-group of patients in which there is significant 
diagnostic uncertainty 
In contrast to those with IPF, many patients with non-IPF interstitial lung 
diseases are not covered by evidence-based diagnostic guidelines therefore 
diagnosis is driven by clinical reasoning and analysis of all available data in a 
multidisciplinary setting. In these situations, a level of disagreement between MDTMs 
is predictable and borne out by the poor level of inter-MDTM agreement in the current 
study for diagnoses of NSIP and hypersensitivity pneumonitis 4,14-16. In particular, it is 
well recognised that the diagnosis of hypersensitivity pneumonitis can be challenging 
as it relies on an array of data, none of which is definitive when considered in 
isolation15, and at least on HRCT, patterns of NSIP, UIP or organising pneumonia 
may be the sole expressions of this disease16-19. The poor MDTM agreement for the 
diagnosis of hypersensitivity pneumonitis in the current study highlights an urgent 
need for international consensus on what hypersensitivity pneumonitis actually is. 
Our use of the weighted kappa to investigate inter-MDTM and interobserver 
agreement on diagnostic probabilities is similar to other studies of diagnostic 
agreement, but warrants particular consideration9. Converting the diagnostic 
likelihoods to a 5-point probability scale enabled examination of the range of 
diagnostic likelihoods from minimal likelihood to pathognomonic using the weighted 
kappa.  As excluding IPF is as important as making a diagnosis of IPF, this 
methodology has allowed us to demonstrate that there is good agreement on the 
likelihood of IPF and as stated previously, this reflects consistent application of 
established diagnostic guidelines for this disease.  In contrast, MDTM agreement on 
the likelihood of hypersensitivity pneumonitis was poor, reinforcing the view that 
MDTMs were unclear on how this diagnosis is made.  
Two separate observations from our study warrant further discussion. First, 13 
patients had an established diagnosis of a connective tissue disease at presentation. 
However, following MDT evaluation, a CTD diagnosis was constructed in an 
additional 8 cases or more by five of the seven MDTMs based on presenting clinical 
symptoms and serology. Separating patients with IIP from those with CTD related ILD 
can be challenging - some patients present with subtle clinical features or serological 
abnormalities which suggest an autoimmune process but do not meet established 
criteria for a specific CTD 20-22. Recently an ERS/ATS task force was formed in order 
to establish consensus on how to classify these patients and a set of diagnostic 
criteria have been suggested 23-25. Following removal of patients with an established 
diagnosis of CTD, our subgroup analysis demonstrated acceptable levels of 
agreement on CTD related ILD (in contrast to hypersensitivity pneumonitis), 
underlying the importance of reaching international consensus on definitions. 
Furthermore, the high frequency of CTD related ILD diagnoses made in the current 
study highlights the importance of formal rheumatology input within the MDTM, which 
might necessarily include face-to-face rheumatologic consultation with patients, 
suspected of having an undiagnosed connective tissue disease.  
Second, it has previously been suggested that dynamic exchanges of clinical, 
radiologic and pathologic information between experts in a multidisciplinary process 
results in higher confidence diagnoses5. In the current study however, the proportion 
of high confidence diagnoses (70% or greater) assigned following MDTM evaluation 
did not increase when compared to the proportion of high confidence diagnoses being 
assigned by the individual components of the MDTM. In the majority of MDTMs, high 
confidence diagnoses were more frequently assigned by radiologists and pathologists, 
when compared to MDTM diagnoses or diagnoses assigned by clinicians. As 
radiologists and pathologists in the current study did not have access to clinical 
information, their interpretation was based almost entirely on pattern recognition, 
which might conceivably result in more confident, but not necessarily more accurate 
diagnoses. Although one benefit of the multidisciplinary process is that diagnoses 
may be challenged and must be publically defended, it is possible that extra 
discussion creates more difficulty in some cases that initially seem straightforward 
when evaluated by individuals in isolation. It must be highlighted however, that in the 
specific case of IPF, MDTMs made the diagnosis of IPF with high confidence more 
frequently than clinicians or radiologists.  
Our methodology has some limitations. As patients were selected from a pre-
antifibrotic drug era, IPF was possibly not as prevalent in our study group as it would 
be now at most referral centres which expend more time in evaluating patients for 
approval for anti-fibrotic treatment. However as discussed, this allowed us to evaluate 
the veracity of MDTM diagnosis for IPF, against outcome. Second, unlike a real-world 
multidisciplinary process, none of the observers had face-to-face consultation with 
patients and therefore did not have the benefit of obtaining a clinical history or 
performing physical examination first-hand. In difficult to characterize patients, a 
clinician’s impression might conceivably be influenced by direct contact with the 
patient in ways, which are not easily and objectively quantified. Equally important, but 
also difficult to assess, is the impact of individual personalities on MDTM diagnosis. 
Arguably a consensus diagnosis at multidisciplinary evaluation might sometimes 
reflect the strongest voice in the room rather than represent true agreement between 
participants. Lastly, the wide range of proportions of high confidence diagnoses 
demonstrated between the different MDTM’s seen in our study may reflect cultural 
influences on the dynamics of multidisciplinary evaluation. These less tangible 
influences could be the focus of further studies.  
In conclusion, our study demonstrates that diagnostic agreement between 
MDTMs is superior to interobserver agreement between clinicians, radiologists and 
pathologists in the setting of DPLD. In particular, inter-MDTM agreement for a 
diagnosis of IPF is good and validated by the greater prognostic significance of an 
IPF diagnosis made by multidisciplinary groups as compared to individual specialists. 
Poor levels of inter-MDTM agreement were demonstrated for NSIP and 
hypersensitivity pneumonitis, the latter of which may relate to the lack of evidence-
based guidelines for diagnosing this disease.  
 
Research in context 
Evidence before this study 
We performed a PubMed search on 17th January 2014 using the search terms 
“diffuse parenchymal lung disease”, “idiopathic pulmonary fibrosis”, “idiopathic 
interstitial pneumonias”, “interobserver agreement”, “diagnosis” and “multidisciplinary 
team” for the period between January 2000 and January 2014. This search was 
extended to 1st December 2015 during the writing of the manuscript. Our search was 
restricted to publications written in English. We identified 7 key publications which 
were pertinent to our study 3-7,9,10. Of these, 4 studies of observer agreement in 
setting of diffuse parenchymal lung disease were identified 5-7,9. All of these studies 
however predated the most up to date ATS/ERS update on the classification of the 
idiopathic interstitial pneumonias4, and not all of them evaluated diagnostic 
agreement between multidisciplinary teams but rather focused on diagnostic 
agreement between individual observers.  
 
Added value of this study 
This study is the first evaluation of inter-multidisciplinary team agreement for 
diagnosis in the setting of diffuse parenchymal lung disease since the updated 2013 
ATS/ERS classification of the idiopathic interstitial pneumonias and the 2011 
ATS/ERS/JRS/ALAT guidelines for the diagnosis and management of idiopathic 
pulmonary fibrosis.  
 
Implications of all the available evidence 
Our study demonstrates that diagnostic agreement between MDTMs is superior to 
interobserver agreement between clinicians, radiologists and pathologists in the 
setting of DPLD. Specifically in IPF, MDTMs have a higher level of agreement on 
diagnosis, assign diagnosis with higher confidence more frequently, and provide 
diagnoses that have greater prognostic significance than clinicians or radiologists in 
the majority of groups.  
This is of particular importance, as accurate and consistent diagnosis of idiopathic 
pulmonary fibrosis is needed if clinical outcome is to be optimised. In contrast, inter-
multidisciplinary team agreement for a diagnosis of hypersensitivity pneumonitis is 
poor, highlighting an urgent need for standardised diagnostic guidelines for this 
disease entity. 
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 Variable Value 
 
Age (Years) 
 
 
60.9 ± 15.5 
 
Gender (M : F) 
 
24:46 
 
Smoking 
(Never/ever/current) 
 
38:24:8 
Established CTD history 
 
13 
 
Biopsied (Y/N) 
 
22/48 
 
DLco (% Predicted) 44.8 ± 14.5 
FEV1 (% Predicted) 73.0 ± 20.5 
FVC (% Predicted) 79.0 ± 19.6 
 
Table 1. Patient demographics. CTD = connective tissue disease. Where appropriate, 
values are expressed as means ± SD.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Diagnosis Number (n=490) 
Connective tissue disease related ILD 146 (29·8%) 
IPF 88 (18·0%) 
Hypersensitivity pneumonitis 46 (9·6%) 
NSIP 42 (9·4%) 
Unclassifiable ILD 38 (7·8%) 
Other 37 (7·6%)  
Sarcoidosis 20 (4·1%) 
Drug-related ILD 18 (3·7%) 
Smoking-related ILD 16 (3·3%) 
Occupational lung disease 14 (2·9%) 
Pleuroparenchymal fibroelastosis 10 (2·0%) 
OP/NSIP overlapping disease 8 (1·6%) 
Organizing pneumonia 7 (1·4%) 
 
Table 2. First choice diagnoses given by 7 multidisciplinary teams for 70 cases of 
diffuse lung disease. ILD = interstitial lung disease, NSIP =non-specific interstitial 
pneumonia, OP = organising pneumonia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MDTM 
(κ) 
Clinicians 
(κ) 
Radiologists 
(κ) 
Pathologists 
(κ) 
Overall 
Total 
(No biopsy) 
0·50  
(0·57) 
0·45 
(0·50) 
0·33 
(0·31) 
0·31 
IPF 
Total 
(No biopsy) 
0·60 
(0·70) 
0·59 
(0·71) 
0·46 
(0·42) 
0·46 
NSIP 
Total 
(No biopsy) 
0·25 
(0·25) 
0·19 
(0·19) 
0·25  
(0·25) 
0·23 
CTD 
Total 
(No biopsy) 
0·64 
(0·73) 
0·57 
(0·62) 
0·10 
(0·11) 
0·22 
HP 
Total 
(No biopsy) 
0·24 
(0·31) 
0·25 
(0·38) 
0·27 
(0·22) 
0·20 
 
 
Table 3. Unweighted Kappa values (κ) for inter-MDTM agreement for overall 
diagnoses and for individual diagnoses of idiopathic pulmonary fibrosis (IPF), 
connective tissue disease related interstitial lung disease (CTD), non-specific 
interstitial pneumonia (NSIP) and hypersensitivity pneumonitis (HP). Unweighted 
Kappa values for inter-observer agreement among clinicians, radiologists, and 
pathologists are also shown. Figures in parentheses are Kappa values in non-
biopsied cases, n=48 (see text). *22/70 (31·4%) cases had surgical lung biopsy 
performed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MDTM 
(κw) 
Clinicians 
(κw) 
Radiologists 
(κw) 
Pathologists 
(κw) 
IPF 
0·71  
(0·64-0·77) 
0·72  
(0·67-0·76) 
0·60  
(0·46-0·66) 
0·58  
(0·45-0·66) 
CTD  
0·73  
(0·68-0·78) 
0·76  
(0·70-0·78) 
0·17  
(0·08-0·31) 
0·21  
(0·06-0·36) 
NSIP 
0·42  
(0·37-0·49) 
0·31  
(0·27-0·41) 
0·32  
(0·26-0·41) 
0·30  
(0·00-0·53) 
HP 
0·29  
(0·24-0·40) 
0·42  
(0·30-0·47) 
0·35  
(0·29-0·43) 
0·26  
(0·10-0·45) 
 
Table 4. Weighted Kappa values (κw) for estimation of diagnostic likelihood for 
individual diagnoses of idiopathic pulmonary fibrosis (IPF), connective tissue disease 
related interstitial lung disease (CTD), non-specific interstitial pneumonia (NSIP) and 
hypersensitivity pneumonitis (HP), expressed as medians with interquartile ranges.  
 
 
 
MDTM 
 (HR, p-value, 95%CI) 
Clinicians 
(HR, p-value, 95%CI) 
Radiologists 
(HR, p-value, 95%CI) 
Team 1 2·67, p = 0·016, 1·21-6·02 2·09, p = 0·085, 0·90-4·86 2·80, p = 0·021, 1·17-6·73 
Team 2 3·44, p = 0·003, 1·54-7·68 2·95, p = 0·008, 1·33-6·59 4·08, p = 0·001, 1·84-9·04 
Team 3 5·30, p < 0·001, 2·26-12·41 3·75, p = 0·002, 1·65-8·51 2·78, p = 0·030, 1·11-6·97 
Team 4 3·99, p = 0·006, 1·49-10·66 3·34, p = 0·007, 1·38-8·00 4·49, p = 0·003, 1·71-12·29 
Team 5 2·61, p = 0·025, 1·12-6·06 2·03, p = 0·100, 0·87-4·69 2·58, p = 0·033, 1·08-6·21 
Team 6 3·36, p = 0·007, 1·40-8·07 4·14, p = 0·002· 1·72-9·97 2·11, p = 0·082, 0·91-4·89 
Team 7 2·43, p = 0·030, 1·09-5·41 2·96, p = 0·007, 1·43-6·55 1·28, p = 0·583, 0·53-3·06 
 
 
Table 5. Univariate Cox regression analysis for mortality according to MDTM, clinician 
and radiologists diagnoses of IPF versus not IPF. (MDTM = multidisciplinary team 
meeting). The results for the MDTMs, clinicians and radiologists are based upon the 
full patient cohort (n=70). *The results for the pathologists are for the subgroup of 
22/70 (31·4%) patients who underwent surgical lung biopsy 
 
 
 
 
  
 
Figure 1. Kaplan-Meier survival curve demonstrating survival differences between 
patients assigned a diagnosis of IPF or not IPF. The entire cohort was separated into 
cases where at least 4/7 MDTMs assigned a first-choice diagnosis of IPF (Blue KM 
curve, HR 6·26, p<0·0001, 95% CI 2·72-14·33), at least 4/7 clinicians assigned a 
first-choice diagnosis of IPF (red KM curve, HR 4·43, p<0·0001, 95% CI 1·94-10·01), 
and at least 4/7 radiologists assigned a first-choice diagnosis of IPF (green KM curve, 
HR 3·76, p=0·002, 95% CI 1·61-8·75). MDTM = multidisciplinary team meeting. See 
Appendix, Figure 7A for number at risk table.  
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Abstract 
 
Background 
To evaluate inter-multidisciplinary team agreement for the diagnosis of diffuse 
parenchymal lung disease (DPLD). 
 
Methods 
Seven multidisciplinary meetings (MDTMs) consisting of at least one clinician, 
radiologist and pathologist, from 7 different countries evaluated 70 cases of diffuse 
lung disease in a two-stage process. First, the clinician, radiologist and pathologist 
(when lung biopsy was performed) evaluated each case and chose likelihoods 
(censored at 5% and summing to 100% in each case) for each of their differential 
diagnoses, without inter-disciplinary consultation. A full MDTM with review of all 
clinical, radiologic and pathologic data followed this. Interobserver agreement and 
inter-MDTM agreement for diagnosis was calculated using Cohen’s kappa coefficient 
or weighted kappa coefficient where appropriate.  
 
Findings   
Inter-MDTM agreement for first choice diagnoses was acceptable (κ = 0·50). 
Idiopathic pulmonary fibrosis made up 18% of all MDTM first choice diagnoses. 
Diagnostic likelihoods for MDTM differential diagnoses were converted to a 5-point 
scale (0 = condition not included in the differential diagnosis, 1 = low probability (5–
25%), 2 = intermediate probability (30–65%), 3 = high probability (70–95%), and 4 = 
pathognomonic (100%)). Inter-MDTM agreement on diagnostic likelihoods was good 
for idiopathic pulmonary fibrosis (IPF) (κw = 0·71) and connective tissue disease 
related interstitial lung disease (CTD-ILD) (κw = 0·73), only moderate for non-specific 
interstitial pneumonia (NSIP) (κw = 0·42) and poor for hypersensitivity pneumonitis 
(HP) (κw = 0·29). MDTMs, clinicians and radiologists respectively gave high 
confidence diagnoses of IPF (>65% likelihood) in 77·3%, 64·6% and 66·3% of cases. 
The prognostic significance of a first choice diagnosis of IPF versus not IPF was 
evaluated for MDTMs, clinicians and radiologists. Greater prognostic 
separationsignificance was demonstrated for an MDTM diagnosis of IPF as compared 
to individual clinician’s diagnosis of IPF in 5/7 MDTMs, radiologist’s diagnosis of IPF 
in 4/7 MDTMs.  
 
Interpretation 
Agreement between MDTMs for diagnosis in diffuse lung disease is acceptable and 
good for a diagnosis of IPF. This is validated by the greater prognostic significance 
separation of an IPF diagnosis made by MDTMs as compared to individual clinicians 
or radiologists. Furthermore, MDTMs made the diagnosis of IPF with higher 
confidence and more frequently than clinicians or radiologists. MDTM agreement for 
diagnosis of NSIP and hypersensitivity pneumonitis is poor, indicating a need for 
international consensus on diagnostic criteria for these diseases.  
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 Introduction 
Diffuse parenchymal lung disease (DPLD) represents a diverse and challenging 
group of pulmonary disorders with varied prognoses and different management 
options. A consistent diagnostic approach to these diseases is essential if clinical trial 
data is to be reliably applied to individual patients. With the recent licensing of two 
new anti-fibrotic idiopathic pulmonary fibrosis (IPF) therapies, accurate and consistent 
diagnosis of IPF is of particular importance if clinical benefit is to be achieved1,2. In 
2002, a joint statement by the American Thoracic Society (ATS) and the European 
Respiratory Society (ERS) on the classification of the idiopathic interstitial 
pneumonias (IIPs) advocated a multidisciplinary diagnostic approach involving 
integration of clinical, radiologic and, when lung biopsy material is available, 
pathologic data3. This approach has been emphasised by several studies in recent 
years and was re-stated in the 2013 ATS/ERS update on the IIPs4-8.  Although this 
recommendation specifically applies to IIP, the multidisciplinary approach has been 
widely adopted as the diagnostic gold standard for DPLD in general5,7. Several 
studies have evaluated interobserver agreement for diagnosis in the setting of DPLD 
5-7,9, but most predate the 2013 ATS/ERS IIP classification update, the 2011 
ATS/ERS/JRS/ALAT statement on the diagnosis and management of IPF and the 
availability of novel anti-fibrotic IPF drugs, all of which may impact decisions on 
diagnosis1,2,4,10. Furthermore, many of these studies focus on individual observers 
rather than agreement between multidisciplinary teams (MDTs) 5-7,9,11. In this study, 
we evaluated the level of inter-MDTM diagnostic agreement between seven 
international centres. 
 
 Methods 
Patient and Multidisciplinary team selection 
For the retrospective examination of clinically indicated data, the institutional ethics 
review board waived informed patient consent. Patients selected for this study 
represented consecutive patients presenting to the interstitial lung disease unit of the 
Royal Brompton & Harefield NHS Foundation Trust and requiring MDTM 
characterisation, between March 1st 2010 and August 31st 2010. Only patients who 
had all their clinical investigations (serology, HRCT and when required, surgical lung 
biopsy) performed at the host institution were included. A total of 7 MDTMs from 7 
different countries (Denmark, France, Italy, Japan, Netherlands, Portugal and the 
United Kingdom), each with specialist expertise in the diagnosis and management of 
DPLD, were invited to participate in the study.  The only prerequisite for participation 
was that each MDT had a regular multidisciplinary meeting for DPLD in place with 
consistent attendance by at least one clinician, radiologist and pathologist. 
 
Evaluation of cases 
The evaluation of each of case took place in two stages· 
  
1. First, clinicians, radiologists and pathologists were required to review the cases 
independently without inter-specialty consultation. Clinicians had access to all 
the presenting clinical information (age, gender, smoking history, history of 
established connective tissue disease (CTD), symptoms including symptoms 
suggestive of a CTD, autoantibody profile, exposure history, medications at 
presentation, bronchoalveolar lavage result if performed, and ACE level if 
performed), pulmonary function tests and HRCT (without access to the original 
HRCT report). Radiologists and pathologists had access only to the age, 
gender and smoking history for the patient, and the HRCT (radiologist) or 
digitized surgical lung biopsy slides (pathologist) at presentation. Specifically, 
pathologists had access to all the pathology data that was available in the form 
of digitized slides (in .svs format) and were viewed using Aperio ImageScope 
12·3 viewing software. This digital viewing application has all the imaging 
functionality normally available to pathologists in routine clinical practice and is 
used by the host institution to evaluate cases referred from outside institutions 
for opinions.  
For each patient, observers were required to select up to 5 differential 
diagnoses and provide a diagnostic likelihood (censored at 5% and summing 
to 100% in each case) from a drop-down menu of diffuse lung diseases 
(Appendix, Table A1). The only stipulation was that diagnoses were 
considered in the context of the current ATS/ERS classification and 
terminology for the IIPs4· 
 
2. Second, the clinician, radiologist and pathologist convened as an MDT and 
reviewed the cases together, again providing up to 5 diagnoses with diagnostic 
likelihoods (also censored at 5% and summing to 100% in each case). All the 
clinical information supplied in the first stage, pulmonary function tests and 
HRCT at presentation as well as digitized surgical lung biopsy slides were 
available to the MDT for review.   
 
 
  
Outcome 
As a means of validating the diagnosis made by MDTM versus individual specialists, 
the mortality of each groups’ diagnosis of IPF was compared. This was achieved by 
separating the entire cohort into a binary IPF diagnosis category (IPF and not IPF) for 
each MDTM, clinician and radiologist based upon assigned diagnoses. The survival 
period for each patient was calculated from the date of referral to the host institution 
to the minimum of date of death, date the patient was last known to be alive or 1st 
June 2015 (end of the study period). Vital status for each patient on the 1st June 2015 
was obtained by evaluating his or her electronic patient record.  
 
Statistical analysis 
Data are given as means with standard deviations (SD), medians with interquartile 
range (IQR) or as number of patients and percentage where appropriate. Statistical 
analyses were performed using STATA (version 12, StataCorp, College Station, 
Texas).  
Cohen’s kappa coefficient (κ) was used to evaluate interobserver and inter-
MDTM agreement for diagnosis. Cohen’s weighted kappa coefficient (κw) was used 
to evaluate interobserver agreement and inter-MDTM agreement for an estimation of 
the probability of each diagnosis. In order to do this, the percentage diagnostic 
likelihood given for each diagnosis was converted to a 5 point scale (0–4), 
representing clinically useful probabilities: 0 = condition not included in the differential 
diagnosis, 1 = low probability (5–25%), 2 = intermediate probability (30–65%), 3 = 
high probability (70–95%), and 4 = pathognomonic (100%). For example, if the 
differential diagnoses given by an MDT were IPF (65% diagnostic likelihood), NSIP 
(25% diagnostic likelihood) and hypersensitivity pneumonitis (10% diagnostic 
likelihood), the probability grades for IPF, NSIP and hypersensitivity pneumonitis for 
this case would be 2, 1 and 1 respectively. Weighted kappa values were calculated 
between paired observers (for statements of interobserver agreement), and between 
paired MDTs (for statements of inter-MDTM agreement) and expressed as median 
values with interquartile ranges for all unique combinations of pairs (21 for 7 
observers or 7 MDTs). Weighting the Kappa coefficient allowed the degree of 
disagreement to be quantified by assigning greater emphasis to large differences 
between scores. Weighted kappa coefficients were categorized as follows: poor (0 < 
κw ≤ 0·20), fair (0·20 < κw ≤ 0·40), moderate (0·40 < κw ≤ 0·60), good (0·60 < κw ≤ 
0·80) and excellent (0·80 < κw ≤ 1·00). This approach has been used in previous 
investigations of interobserver agreement for diagnosis in diffuse lung diseases9,11· 
In addition to the above, in each case the first choice diagnosis was 
considered “low confidence” (diagnostic likelihood <70%), or “high confidence” (70% 
or greater diagnostic likelihood). These categories were based on those the 
diagnostic likelihood categories used to assess the clinical probability of pulmonary 
embolism in the PIOPED study12. 
Univariate Cox regression analysis was used to identify associations between 
mortality and MDTM, clinician and radiologist diagnoses in terms of IPF versus “not 
IPF”. Reported hazards ratios are for diagnosis of IPF versus “not IPF”.  The 
assumptions of proportional hazards were tested by 1) visual inspection the log-log 
plot of survival, 2) comparison of the Kaplan-Meier observed survival curves with the 
Cox predicted curves for the same variable and 3) graphical and formal analysis of 
Schoenfeld residuals (analysis not shown). Results are reported as hazard ratios, p-
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values and 95% confidence intervals and graphically as Kaplan-Meier survival curves. 
 
 
Role of the funding source: 
The sponsors of the study did not have any role in the design, data collection, 
analysis and interpretation, nor in the writing of the report. The corresponding author 
had full access to all of the data and the final responsibility to submit for publication.
   
 
 
 
Results 
 
Patient population 
A total of 113 consecutive new referrals who required local MDTM characterisation 
were identified from the clinical database between March 1st 2010 and August 31st 
2010. Of these, 43/113 (38·1%) were excluded on the basis that a) their initial work-
up HRCT scan had been performed at the referring institution (n=29), b) their lung 
function had been performed at the referring institution (n=4), or c) surgical lung 
biopsy had been performed by the referring institution (n=10), (Table 1 and Appendix, 
Figure A1). The remaining 70 cases made up the final study population. Basic patient 
demographics are shown in the Appendix, Table A2. Of note, thirteen (19%) had an 
established diagnosis of a connective tissue disease at the time of presentation to the 
host institution and 22/70 (34·1%) underwent surgical lung biopsy at the host 
institution. In cases where surgical lung biopsy was not performed (48/70), a 
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confident diagnosis had been made without the need for surgical lung biopsy material. 
Vital status was known for all patients at the end of the study period. These 70 
patients resulted in the assignment of 490 first choice MDTM diagnoses (70 patients 
evaluated by 7 MDTMs). First choice diagnoses are shown in Table 2. The NSIP/OP 
overlap ILD category was combined with the NSIP category and diagnosis categories 
whose frequency was less that 10% of the total number of first choice diagnoses were 
combined into an ‘others’ diagnosis category. The final diagnosis categories were 
then as follows: CTD related ILD (n=146/490, 27·8%), IPF (n=88/490, 18·0%), 
idiopathic NSIP (n=50/490, 10·2%), hypersensitivity pneumonitis (n=46/490, 9·4%) 
and others (n=160/490, 32·7%). Subsequent analyses focused on these four primary 
diagnosis categories.  
 
 
 
Inter-multidisciplinary team and inter-observer agreement for first choice diagnosis 
Inter-MDTM agreement and interobserver agreement (for clinicians, radiologists and 
pathologists) for first choice diagnosis is shown in Table 3. Overall inter-MDTM 
agreement for first choice diagnosis was moderate (κ = 0·50). Inter-MDTM agreement 
for a first choice diagnosis of IPF was good (κ = 0·60), for a first choice diagnosis of 
CTD related ILD also good (κ = 0·64), but poor for first choice diagnoses of idiopathic 
NSIP (κ = 0·25) and hypersensitivity pneumonitis (κ = 0·24). On subgroup analysis in 
patients in whom lung biopsy was not performed (n=48/70, 68·6%), overall inter-
MDTM agreement for diagnosis was greater (κ = 0·57) with inter-MDTM agreement 
for first choice diagnoses of IPF, CTD related ILD and hypersensitivity pneumonitis 
also greater. Overall inter-observer agreement among clinicians for first choice 
diagnosis was moderate (κ = 0·45) and fair between radiologists (κ = 0·33) and 
pathologists (κ = 0·31) (Table 3.).  
 
 
 
Inter-multidisciplinary team and inter-observer agreement for diagnosis probabilities  
There was fair to good inter-MDTM agreement on the estimation of diagnostic 
likelihood of the 4 most prevalent diagnoses as shown in Table 4. In particular, inter-
MDTM agreement on the diagnostic likelihood of IPF was good (κw= 0·71, IQR 0·64-
0·77), and good for CTD related ILD (κw= 0·73, IQR 0·68-0·78) but moderate for 
idiopathic NSIP (κw = 0·41 IQR 0·37-0·49) and fair for hypersensitivity pneumonitis 
(κw = 0·29 IQR 0·24-0·40). Subgroup analysis of inter-MDTM agreement on the 
estimation of diagnostic likelihood of IPF in patients without lung biopsy was good (κw 
= 0·78 IQR 0·74-0·83). 
Agreement between clinicians on the probability of a diagnosis of IPF or CTD-
related ILD was superior to agreement on the probability of a diagnosis of idiopathic 
NSIP or hypersensitivity pneumonitis. Agreement between radiologists or pathologists 
on the probability of a diagnosis of IPF was superior to agreement on the probability 
of a diagnosis of CTD-related ILD, idiopathic NSIP or hypersensitivity pneumonitis.  
 
Subgroup analysis of inter-MDTM agreement in patients without an established 
diagnosis of a connective tissue disease. 
At the time of patient selection, 13/70 (18·6%) patients had an established diagnosis 
of a CTD (systemic sclerosis = 7, rheumatoid arthritis = 3, Sjögren’s syndrome = 2, 
mixed connective tissue disease = 1). In order to investigate if high agreement in 
these 13 cases caused a spurious increase in agreement on non-CTD diagnoses and 
in particular, impacting agreement on a diagnosis of IPF, a subgroup analysis was 
performed in the remainder of the cohort (n=57/70, 81·4%). On this analysis, although 
inter-MDTM agreement for a first choice diagnosis of CTD related ILD decreased (κ = 
0.42), no significant change in inter-MDTM agreement was observed for a first choice 
diagnosis of IPF (κ = 0·58), idiopathic NSIP (κ = 0·24) or hypersensitivity pneumonitis 
(k = 0·23) (Appendix, Table A2). 
 
Diagnostic confidence for first choice diagnoses  
A total of 347/490 (70·1%) first choice MDT diagnoses were made with high 
confidence (diagnostic likelihood 70–95% = high confidence, 100% = pathognomonic). 
The median prevalence of first choice MDT diagnoses made with high confidence 
was 67·1% (IQR 54·3-88·8). The median prevalence of first choice diagnoses made 
with high confidence by clinicians, radiologists or pathologists was 58·9% (IQR 52·9-
71·4), 68·6% (IQR 35·7-85·7) and 72·7% (IQR 59·1-81·8) respectively (Appendix, 
Table A3). On subgroup analysis in the 48/70 (68·6%) patients who did not undergo 
surgical lung biopsy 237/336 (70·5%) first choice MDT diagnoses were made with 
high confidence. Within this subgroup the median prevalence of first choice 
diagnoses made with high confidence by the MDTs, clinicians or radiologists were 
68·7% (IQR 52·8-87·5), 60·4% (IQR 37·5-75·0) and 66·6% (IQR 39·6-83·3) 
respectively.  
For the diagnosis of IPF, supportive non-significant trends for higher 
confidence diagnoses by MDTMs (68/88, 77·.3%) as compared to clinicians (62/96, 
64·6%) or radiologists (57/86, 66·3%) were demonstrated (p = 0·.23)· In the 22/70 
(31·.4%) cases that underwent surgical lung biopsy (therefore a total of 154 
diagnoses rendered by 7 pathologists), 15/154 (9·7%) cases were assigned a 
diagnosis of IPF, of which 12/15 (80·0%) were assigned with high confidence.  
      A review of the cases where the pathologists 
gave a first choice diagnosis of IPF (15/154 cases, 154 = 22 cases x 7 pathologists) 
was performed to ascertain if, in cases where surgical lung biopsy was performed and 
the first choice pathologic diagnosis was IPF, the final MDTM diagnosis was usually 
IPF. In 6/15 cases, despite the pathologist giving a first choice diagnosis of IPF, the 
final MDTM first choice diagnosis was not IPF. Furthermore, in only 2/15 cases, was 
IPF not already suggested by either the clinician or radiologist in that MDTM (Table 
A5). 
 
 
 
Evaluation of the prognostic significance of an MDTM diagnosis of IPF  
On univariate Cox regression analysis, the multidisciplinary distinction between IPF 
and other diagnoses demonstrated non-significant trends toward greater prognostic 
separation (as judged by hazard ratio p values)  than the clinician distinction (in 5/7 
groups) or the radiologist distinction (in 4/7 groups) (Table 5).On univariate Cox 
regression analysis, MDTM diagnosis of IPF demonstrated greater prognostic 
significance than clinician’s diagnosis of IPF in 5/7 multidisciplinary groups, and in 
radiologist’s diagnosis of IPF in 4/7 groups (Table 4). A graphical presentation of the 
KM-survival curves for the categorisation of first-choice diagnosis as IPF or not IPF in 
at least 4/7 MDTMs, 4/7 clinicians and 4/7 radiologists is shown in Figure 1. The 
same analysis for pathologists’ diagnosis of IPF failed to reach statistical significance 
for 5/7 pathologists, probably because of the small subgroup size (n=22) and low 
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prevalence of IPF within this subgroup (15/154, pathologists’ first-choice diagnoses 
were IPF) (Appendix, Table A4 and A5).   
 
 
 
 
 
 
 
 
 
 
 
Discussion 
We have demonstrated for the first time, that there is acceptable diagnostic 
agreement between multidisciplinary groups in the setting of diffuse parenchymal lung 
disease and that this agreement is validated by the greater prognostic significance of 
an IPF diagnosis made by multidisciplinary groups as compared to individual 
clinicians and radiologists. Furthermore, MDTMs make the diagnosis of IPF with high 
confidence, more frequently than clinicians or radiologists.  
 Since the publication of the ATS/ERS 2002 consensus statement on the 
classification of the IIPs, multidisciplinary evaluation of DPLD has been widely 
adopted as the diagnostic gold standard3,4. This diagnostic approach has been 
investigated in a limited way in several settings. Flaherty et al. examined the 
formulation of diagnosis in a cohort of diffuse lung diseases against interobserver 
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agreement and diagnostic confidence within a single multidisciplinary team 
(consisting of 3 clinicians, 2 radiologists and 2 pathologists) and demonstrated that 
diagnostic agreement between observers improved with successive integration of 
clinical, radiologic and pathologic data5. In a second study, Flaherty et al. expanded 
these findings by demonstrating higher levels of agreement between academic 
physicians, radiologists and pathologists for diagnosis in diffuse lung disease when 
compared with their community counterparts7. Several years later, Thomeer et al. 
demonstrated in a cohort of patients included in an IPF trial, high accuracy for a 
clinical diagnosis of IPF made by 6 respiratory physicians from different European 
centres6. A limitation of these studies is that not all evaluated agreement between 
different MDTs for diagnosis 5, one focuses specifically on the diagnosis of IPF6 and 
all of them predate the most recent 2013 ATS/ERS IIP update4-7,9. The current study 
is the first to evaluate inter-MDTM agreement for diagnosis in diffuse lung disease 
since publication of the 2013 ATS/ERS update on the classification of the IIPs.   
With the recent licensing of two new drugs for treatment of IPF in mild to 
moderate disease, early and accurate diagnosis of IPF is crucial. Our study 
demonstrates that inter-MDTM agreement for the diagnosis of IPF is good, with 
clinicians demonstrating only marginally inferior levels of agreement, as compared to 
MDTMs for this diagnosis. On subgroup analysis in patients without surgical lung 
biopsy, inter-MDTM agreement and interobserver agreement between clinicians for 
the diagnosis of IPF improved and were again, almost equal. As evidence-based 
diagnostic criteria for IPF are now clearly defined and in many IPF patients, are 
relatively easily applied, this near parity of agreement between MDTMs and between 
clinicians is not surprising 4,10. For example, in a patient with classic appearances for 
usual interstitial pneumonia (UIP) on HRCT, a rapidly progressive disease course and 
no identifiable triggers, multidisciplinary discussion is unlikely to alter a clinician’s 
initial impression of IPF. Our findings suggest that formal multidisciplinary input may 
not be necessary in every case of suspected IPF if expert clinical evaluation is 
available, which may be of particular relevance to centres with limited access to 
appropriate radiology or pathology expertise13 .  
A strength of our findings is that the greater agreement on multidisciplinary 
diagnosis is mirrored by the trend toward greater prognostic significance separation of 
a multidisciplinary diagnosis distinction betweenof IPF and other diagnoses when 
compared to the clinicians’ or radiologists’ distinction. To demonstrate this, patients 
were necessarily selected from 2010 to allow an analysis of 5-year survival.  An 
added advantage of this approach was that these patients were referred in a pre-
antifibrotic drug era, therefore mortality differences between IPF and non-IPF patients 
were not confounded by antifibrotic therapy. The fact that trends are present but 
inconclusive may reflect powering limitations but may also indicate that 
multidisciplinary discussion adds prognostic value in the sub-group of patients in 
which there is significant diagnostic uncertainty 
In contrast to those with IPF, many patients with non-IPF interstitial lung 
diseases are not covered by evidence-based diagnostic guidelines therefore 
diagnosis is driven by clinical reasoning and analysis of all available data in a 
multidisciplinary setting. In these situations, a level of disagreement between MDTMs 
is predictable and borne out by the poor level of inter-MDTM agreement in the current 
study for diagnoses of NSIP and hypersensitivity pneumonitis 4,14-16. In particular, it is 
well recognised that the diagnosis of hypersensitivity pneumonitis can be challenging 
as it relies on an array of data, none of which is definitive when considered in 
isolation15, and at least on HRCT, patterns of NSIP, UIP or organising pneumonia 
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may be the sole expressions of this disease16-19. The poor MDTM agreement for the 
diagnosis of hypersensitivity pneumonitis in the current study highlights an urgent 
need for international consensus on what hypersensitivity pneumonitis actually is. 
Our use of the weighted kappa to investigate inter-MDTM and interobserver 
agreement on diagnostic probabilities is similar to other studies of diagnostic 
agreement, but warrants particular consideration9. Converting the diagnostic 
likelihoods to a 5-point probability scale enabled examination of the range of 
diagnostic likelihoods from minimal likelihood to pathognomonic using the weighted 
kappa.  As excluding IPF is as important as making a diagnosis of IPF, this 
methodology has allowed us to demonstrate that there is good agreement on the 
likelihood of IPF and as stated previously, this reflects consistent application of 
established diagnostic guidelines for this disease.  In contrast, MDTM agreement on 
the likelihood of hypersensitivity pneumonitis was poor, reinforcing the view that 
MDTMs were unclear on how this diagnosis is made.  
Two separate observations from our study warrant further discussion. First, 13 
patients had an established diagnosis of a connective tissue disease at presentation. 
However, following MDT evaluation, a CTD diagnosis was constructed in an 
additional 8 cases or more by five of the seven MDTMs based on presenting clinical 
symptoms and serology. Separating patients with IIP from those with CTD related ILD 
can be challenging - some patients present with subtle clinical features or serological 
abnormalities which suggest an autoimmune process but do not meet established 
criteria for a specific CTD 20-22. Recently an ERS/ATS task force was formed in order 
to establish consensus on how to classify these patients and a set of diagnostic 
criteria have been suggested 23-25. Following removal of patients with an established 
diagnosis of CTD, our subgroup analysis demonstrated acceptable levels of 
agreement on CTD related ILD (in contrast to hypersensitivity pneumonitis), 
underlying the importance of reaching international consensus on definitions. 
Furthermore, the high frequency of CTD related ILD diagnoses made in the current 
study highlights the importance of formal rheumatology input within the MDTM, which 
might necessarily include face-to-face rheumatologic consultation with patients, 
suspected of having an undiagnosed connective tissue disease.  
Second, it has previously been suggested that dynamic exchanges of clinical, 
radiologic and pathologic information between experts in a multidisciplinary process 
results in higher confidence diagnoses5. In the current study however, the proportion 
of high confidence diagnoses (70% or greater) assigned following MDTM evaluation 
did not increase when compared to the proportion of high confidence diagnoses being 
assigned by the individual components of the MDTM. In the majority of MDTMs, high 
confidence diagnoses were more frequently assigned by radiologists and pathologists, 
when compared to MDTM diagnoses or diagnoses assigned by clinicians. As 
radiologists and pathologists in the current study did not have access to clinical 
information, their interpretation was based almost entirely on pattern recognition, 
which might conceivably result in more confident, but not necessarily more accurate 
diagnoses. Although one benefit of the multidisciplinary process is that diagnoses 
may be challenged and must be publically defended, it is possible that extra 
discussion creates more difficulty in some cases that initially seem straightforward 
when evaluated by individuals in isolation. It must be highlighted however, that in the 
specific case of IPF, MDTMs made the diagnosis of IPF with high confidence more 
frequently than clinicians or radiologists.  
Our methodology has some limitations. As patients were selected from a pre-
antifibrotic drug era, IPF was possibly not as prevalent in our study group as it would 
be now at most referral centres which expend more time in evaluating patients for 
approval for anti-fibrotic treatment. However as discussed, this allowed us to evaluate 
the veracity of MDTM diagnosis for IPF, against outcome. Second, unlike a real-world 
multidisciplinary process, none of the observers had face-to-face consultation with 
patients and therefore did not have the benefit of obtaining a clinical history or 
performing physical examination first-hand. In difficult to characterize patients, a 
clinician’s impression might conceivably be influenced by direct contact with the 
patient in ways, which are not easily and objectively quantified. Equally important, but 
also difficult to assess, is the impact of individual personalities on MDTM diagnosis. 
Arguably a consensus diagnosis at multidisciplinary evaluation might sometimes 
reflect the strongest voice in the room rather than represent true agreement between 
participants. Lastly, the wide range of proportions of high confidence diagnoses 
demonstrated between the different MDTM’s seen in our study may reflect cultural 
influences on the dynamics of multidisciplinary evaluation. These less tangible 
influences could be the focus of further studies.  
In conclusion, our study demonstrates that diagnostic agreement between 
MDTMs is superior to interobserver agreement between clinicians, radiologists and 
pathologists in the setting of DPLD. In particular, inter-MDTM agreement for a 
diagnosis of IPF is good and validated by the greater prognostic significance of an 
IPF diagnosis made by multidisciplinary groups as compared to individual specialists. 
Poor levels of inter-MDTM agreement were demonstrated for NSIP and 
hypersensitivity pneumonitis, the latter of which may relate to the lack of evidence-
based guidelines for diagnosing this disease.  
 
Research in context 
Evidence before this study 
We performed a PubMed search on 17th January 2014 using the search terms 
“diffuse parenchymal lung disease”, “idiopathic pulmonary fibrosis”, “idiopathic 
interstitial pneumonias”, “interobserver agreement”, “diagnosis” and “multidisciplinary 
team” for the period between January 2000 and January 2014. This search was 
extended to 1st December 2015 during the writing of the manuscript. Our search was 
restricted to publications written in English. We identified 7 key publications which 
were pertinent to our study 3-7,9,10. Of these, 4 studies of observer agreement in 
setting of diffuse parenchymal lung disease were identified 5-7,9. All of these studies 
however predated the most up to date ATS/ERS update on the classification of the 
idiopathic interstitial pneumonias4, and not all of them evaluated diagnostic 
agreement between multidisciplinary teams but rather focused on diagnostic 
agreement between individual observers.  
 
Added value of this study 
This study is the first evaluation of inter-multidisciplinary team agreement for 
diagnosis in the setting of diffuse parenchymal lung disease since the updated 2013 
ATS/ERS classification of the idiopathic interstitial pneumonias and the 2011 
ATS/ERS/JRS/ALAT guidelines for the diagnosis and management of idiopathic 
pulmonary fibrosis.  
 
Implications of all the available evidence 
Our study demonstrates that diagnostic agreement between MDTMs is superior to 
interobserver agreement between clinicians, radiologists and pathologists in the 
setting of DPLD. Specifically in IPF, MDTMs have a higher level of agreement on 
diagnosis, assign diagnosis with higher confidence more frequently, and provide 
diagnoses that have greater prognostic significance than clinicians or radiologists in 
the majority of groups.  
This is of particular importance, as accurate and consistent diagnosis of idiopathic 
pulmonary fibrosis is needed if clinical outcome is to be optimised. In contrast, inter-
multidisciplinary team agreement for a diagnosis of hypersensitivity pneumonitis is 
poor, highlighting an urgent need for standardised diagnostic guidelines for this 
disease entity. 
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Variable Value 
 
Age (Years) 
 
 
60.9 ± 15.5 
 
Gender (M : F) 
 
24:46 
 
Smoking 
(Never/ever/current) 
 
38:24:8 
Established CTD history 
 
13 
 
Biopsied (Y/N) 
 
22/48 
 
DLco (% Predicted) 44.8 ± 14.5 
FEV1 (% Predicted) 73.0 ± 20.5 
FVC (% Predicted) 79.0 ± 19.6 
 
Table 1. Patient demographics. CTD = connective tissue disease. Where appropriate, 
values are expressed as means ± SD.   
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Diagnosis Number (n=490) 
Connective tissue disease related ILD 146 (29·8%) 
IPF 88 (18·0%) 
Hypersensitivity pneumonitis 46 (9·46%) 
NSIP 42 (9·64%) 
Unclassifiable ILD 38 (7·8%) 
Other 37 (7·6%)  
Sarcoidosis 20 (4·1%) 
Drug-related ILD 18 (3·7%) 
Smoking-related ILD 16 (3·3%) 
Occupational lung disease 14 (2·9%) 
Pleuroparenchymal fibroelastosis 10 (2·0%) 
OP/NSIP overlapping disease 8 (1·6%) 
Organizing pneumonia 7 (1·4%) 
 
Table 2. First choice diagnoses given by 7 multidisciplinary teams for 70 cases of 
diffuse lung disease. ILD = interstitial lung disease, NSIP =non-specific interstitial 
pneumonia, OP = organising pneumonia.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MDTM 
(κ) 
Clinicians 
(κ) 
Radiologists 
(κ) 
Pathologists 
(κ) 
Overall 
Total 
(No biopsy) 
0·50  
(0·57) 
0·45 
(0·50) 
0·33 
(0·31) 
0·31 
IPF 
Total 
(No biopsy) 
0·60 
(0·70) 
0·59 
(0·71) 
0·46 
(0·42) 
0·46 
NSIP 
Total 
(No biopsy) 
0·25 
(0·25) 
0·19 
(0·19) 
0·25  
(0·25) 
0·23 
CTD 
Total 
(No biopsy) 
0·64 
(0·73) 
0·57 
(0·62) 
0·10 
(0·11) 
0·22 
HP 
Total 
(No biopsy) 
0·24 
(0·31) 
0·25 
(0·38) 
0·27 
(0·22) 
0·20 
 
 
Table 3. Unweighted Kappa values (κ) for inter-MDTM agreement for overall 
diagnoses and for individual diagnoses of idiopathic pulmonary fibrosis (IPF), 
connective tissue disease related interstitial lung disease (CTD), non-specific 
interstitial pneumonia (NSIP) and hypersensitivity pneumonitis (HP). Unweighted 
Kappa values for inter-observer agreement among clinicians, radiologists, and 
pathologists are also shown. Figures in parentheses are Kappa values in non-
biopsied cases, n=48 (see text). *22/70 (31·4%) cases had surgical lung biopsy 
performed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MDTM 
(κw) 
Clinicians 
(κw) 
Radiologists 
(κw) 
Pathologists 
(κw) 
IPF 
0·71  
(0·64-0·77) 
0·72  
(0·67-0·76) 
0·60  
(0·46-0·66) 
0·58  
(0·45-0·66) 
CTD  
0·73  
(0·68-0·78) 
0·76  
(0·70-0·78) 
0·17  
(0·08-0·31) 
0·21  
(0·06-0·36) 
NSIP 
0·42  
(0·37-0·49) 
0·31  
(0·27-0·41) 
0·32  
(0·26-0·41) 
0·30  
(0·00-0·53) 
HP 
0·29  
(0·24-0·40) 
0·42  
(0·30-0·47) 
0·35  
(0·29-0·43) 
0·26  
(0·10-0·45) 
 
Table 4. Weighted Kappa values (κw) for estimation of diagnostic likelihood for 
individual diagnoses of idiopathic pulmonary fibrosis (IPF), connective tissue disease 
related interstitial lung disease (CTD), non-specific interstitial pneumonia (NSIP) and 
hypersensitivity pneumonitis (HP), expressed as medians with interquartile ranges.  
 
 
 
MDTM 
 (HR, p-value, 95%CI) 
Clinicians 
(HR, p-value, 95%CI) 
Radiologists 
(HR, p-value, 95%CI) 
Team 1 2·.67, p = 0·.016, 1·21-6·02 2·.09, p = 0·085, 0·90-4·86 2·.80, p = 0·021, 1·17-6·73 
Team 2 3·.44, p = 0·003, 1·54-7·68 2·.95, p = 0·008, 1·33-6·59 4·.08, p = 0·001, 1·84-9·04 
Team 3 5·.30, p < 0·001, 2·26--
12·41 
3·.75, p = 0·002, 1·65-8·51 2·.78, p = 0·030, 1·11-6·97 
Team 4 3·.99, p = 0·006, 1·49-
10·66 
3·.34, p = 0·007, 1·38-8·00 4·.49, p = 0·003, 1·71-12·29 
Team 5 2·.61, p = 0·025, 1·12-6·06 2·.03, p = 0·100, 0·87-4·69 2·.58, p = 0·033, 1·08-6·21 
Team 6 3·.36, p = 0·007, 1·40-8·07 4·.14, p = 0·002· 1·72-9·97 2·.11, p = 0·082, 0·91-4·89 
Team 7 2·.43, p = 0·.030, 1·.09-
5·.41 
2·.96, p = 0·007, 1·43-6·55 1·.28, p = 0·583, 0·53-3·06 
 
 
Table 5. Univariate Cox regression analysis for mortality according to MDTM, clinician 
and radiologists diagnoses of IPF versus not IPF. (MDTM = multidisciplinary team 
meeting). The results for the MDTMs, clinicians and radiologists are based upon the 
full patient cohort (n=70). *The results for the pathologists are for the subgroup of 
22/70 (31·4%) patients who underwent surgical lung biopsysy 
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Figure 1. Kaplan-Meier survival curve demonstrating survival differences between 
patients assigned a diagnosis of IPF or not IPF. The entire cohort was separated into 
cases where at least 4/7 MDTMs assigned a first-choice diagnosis of IPF (Blue KM 
curve, HR 6·26, p<0·0001, 95% CI 2·72-14·33), at least 4/7 clinicians assigned a 
first-choice diagnosis of IPF (red KM curve, HR 4·43, p<0·0001, 95% CI 1·94-10·01), 
and at least 4/7 radiologists assigned a first-choice diagnosis of IPF (green KM curve, 
HR 3·76, p=0·002, 95% CI 1·61-8·75). MDTM = multidisciplinary team meeting. See 
Appendix, Figure 7A for number at risk table.  
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17th March 2016, 
Diana Stanley, 
Editorial Office 
Lancet Respiratory Medicine 
 
Re : Manuscript THELANCETRM-D-16-0035 
 
Dear Professor Stanley, 
 
We are delighted to be given the opportunity to revise our manuscript. We hope 
that we have addressed all of the your comments to your satisfaction and in 
particular thank you for taking into consideration our concerns regarding how the 
data pertaining to the pathologists in our study should be displayed.  
 
Specific Editorial points to be addressed: 
 
1. We understand your concerns with adding the pathologist survival data to the 
main paper and table. We wonder though if it would be worth doing the analysis in 
the appendix so readers can see if they want to? 
 
Many thanks to taking our concerns regarding this into consideration. We have 
added this data to the Appendix (Table A5) as suggested.  
 
*Reply to Reviewers Comments
2. You say that a total of 22/70 (34.1%) of cases underwent surgical lung biopsy. Can 
you clarify why the others weren't biopsied - confident diagnosis or not suitable 
candidates? 
 
Based upon a review of the patients electronic patient records, in all 48/70 cases 
who did not undergo surgical lung biopsy, a confident diagnosis was made without 
the need to proceed to lung biopsy.  We have added this to the manuscript 
(Results, patient population) 
 
3. Please clarify that clearer you weren't using the diagnostic classifications of PE 
from the PIOPED study but the criteria for diagnostic likelihood. I think this is where 
confusion lies. 
 
Thank you. We have modified the manuscript accordingly.  
 
4. Please add to appendix and mention in main paper: 
we reviewed the cases where the pathologists gave a first choice diagnosis of IPF 
(15/154 cases, 154 = 22 cases x 7 pathologists). We have now included this in tabular 
form in the appendix (Table A5). You will see that in only 2 of these 15 cases was IPF 
not already given as a first choice diagnosis by either the clinician or radiologist 
(marked with *). In 6/15 cases, despite the pathologist giving a first choice diagnosis 
of IPF, the final MDTM first choice diagnosis was not IPF. 
 
Many thanks for this suggestion. We have added (Results, diagnostic confidence 
for first choice diagnoses): 
 
“A review of the cases where the pathologists gave a first choice diagnosis of IPF 
(15/154 cases, 154 = 22 cases x 7 pathologists) was performed to ascertain if, in 
cases where surgical lung biopsy was performed and the first choice pathologic 
diagnosis was IPF, the final MDTM diagnosis was usually IPF. In 6/15 cases, despite 
the pathologist giving a first choice diagnosis of IPF, the final MDTM first choice 
diagnosis was not IPF. Furthermore, in only 2/15 cases, was IPF not already 
suggested by either the clinician or radiologist in that MDTM (Table A5).” 
 
5. Please add some information in a table or in appendix about age, gender, smoking 
history, history of established connective tissue disease and number of cases that 
underwent lung biopsy and if you have it FEV1 for the patient population so the 
reader can get an idea of what it was like. 
 
We have included a table (Table A2) in the appendix which shows this data, as well 
as the % predicted Dlco, FEV1 and FVC.  
 
General editorial comments to be addressed: 
 
 
1. Please check with your co-authors, and confirm, that all names are spelt correctly, 
and affiliations listed correctly. We cannot guarantee that we will be able to correct 
names and affiliations after publication of your article. 
 
Many thanks – we have checked this.  
 
2. The study title should have a descriptor—ie, randomised trial, case-control study, 
prospective analysis, population-based study 
 
Many thanks – we have adjusted the title as requested (Multicentre evaluation of 
multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal 
lung disease: a case cohort study) 
 
3. Please supply (after author names on the title page) one preferred degree per 
author and indicate in the authorship if any authors are full professors. 
 
Many thanks – we have added a title page as instructed 
 
4. Please confirm that your study conforms to the relevant guidelines by completing 
and returning the checklist. 
 
STROBE - Observational studies —
 http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61602-
X/fulltext 
 
Many thanks – we have included the STROBE checklist with the statement “We 
have followed this checklist and we can confirm that our manuscript stratifies the 
recommendations in each section detailed below”. 
 
5. It is Lancet style is to give actual numbers (nominator and denominator) together 
with percentages. 
 
Many thanks – we have made these changes. 
 
6. Lancet style is to provide exact p values, unless p<0.0001 (if this is the case, then 
please revise to the latter). You need only give the p-value to 2 decimal places for 
non-significant results (ie p=0.87). 
 
Many thanks – we have made these changes 
 
7. The Lancet group are very supportive of protocol-based research and so have 
recently decided to encourage authors to post the protocol document on a publicly 
accessible website; a margin link to the website will then be put in the paper. Would 
you like to do this for your protocol?  If so, please send us the protocol link with your 
final corrections. Please note that if you do wish to do this then the weblink should 
not be temporary. 
 
Not applicable 
 
8. Lancet style is to have a 'Role of the funding source' at the end of the methods. 
The following points need to be addressed in the "Role of the funding source" 
statement: 
 
* The role of the sponsors in the study design. 
 
* The role of the sponsors in the collection, analysis, or interpretation of the data. 
 
* The role of the sponsors in the writing of the report. 
 
* Those who had access to the raw data (by author initials). 
 
If the funding source had no role then this should be stated. Please also add to this 
section (if true): "The corresponding author had full access to all of the data and the 
final responsibility to submit for publication." 
 
Many thanks – we have added the following after the methods section: 
 
“Role of the funding source: 
The sponsors of the study did not have any role in the design, data collection, 
analysis and interpretation, nor in the writing of the report. The corresponding 
author had full access to all of the data and the fi nal responsibility to submit for 
publication.”  
 
9.  If you have claimed a first, please reword to: "To our knowledge… this is the first 
time...", since you can never be 100% sure. 
 
Not applicable 
 
10. We require TWO author signatures from every authors listed. All authors need to 
sign this form: http://download.thelancet.com/flatcontentassets/authors/tlrm-
author-signatures.pdf AND each author must additionally complete and return this 
form:  http://download.thelancet.com/flatcontentassets/authors/icmje-coi-
form.pdf. You can return these by email if it is easier. 
 
We currently have all the author forms except for Dr Poletti. We don't have any 
conflict of interest forms. 
 
We have attached these documents.  
 
11. Please add a conflict of interest statement to the end of your paper, as per 
Lancet style. These statements should exactly match those given on your signed 
conflict of interest forms. If there are none then please state "The authors declared 
no conflicts of interest" or "The other authors declared no conflicts of interest." 
 
We have added this to the end of the manuscript.  
 
12. Please add an Author contributions section to the end of your paper before the 
references, as per Lancet style. These statements should exactly match those given 
on your signed forms. Authors should be referred to by their initials in this section. 
 
We have added this after the conflict of interest statement and before the 
references section.  
 
 
13. References should be in Vancouver style. For references with six authors or 
fewer, all authors should be listed. For those with seven or more authors, then just 
the first three authors and 'et al' should be listed. Please ensure that you do not use 
endnotes and footnotes in Word as they are difficult to edit. 
 
Completed 
 
14. All web references should have the date they were last accessed. 
 
Not applicable 
 
15. All abstracts and references in press should be updated with DOIs or page 
numbers as appropriate. For papers listed in references that are "in press" we need 
to see a galley proof and/or letter from the publisher stating that it is "in press" as 
well as (where known) the full expected citation (ie, publication date/volume/issue 
etc). References that are "submitted" should be removed and citations in the text 
replaced with "(unpublished data; authors)". 
 
Completed 
 
16. Please supply all tables in an editable format as Word files (not excel or fdf/pdf). 
Each row of data should be in a separate line. Please ensure that rows and columns 
are not tabbed; data should be entered in cell form. 
 
Completed 
 
17. Please supply figures as editable high-resolution EPS format, exported directly 
from your statistical package if possible, rather than embedded in a Word file. (TIF 
for photographs). 
 
Not applicable  
 
18. Please add number at risk in each group for each time point on your K-M curves. 
 
Completed. 
 
19. It is not Lancet policy to edit or style supplementary material for the web; 
however, this material will still be hosted on our website as a pdf of the author 
supplied file. Please style your supplementary material as per the guidelines found 
at http://www.thelancet.com/lancet-information-for-authors/web-extra-guidelines. 
Please note that we will be unable to correct any errors in the webappendix 
following publication; as such, please check carefully when submitting. Please supply 
the webappendix as a single PDF file, with the pages paginated. 
 
We have submitted the appendix as a PDF file. 
 
20. Please ensure that main outcome measures include a result for each group plus a 
point estimate (eg, RR, HR) with a measure of precision (95% CI) for the difference 
between groups. 
 
Completed. 
 
 
 
 
Reviewers' comments: 
 
Reviewer #1: The authors have addressed this reviewer's comments and amended 
the manuscript accordingly. 
 
Many thanks for your work.  
 
Reviewer #4: 
the curves for Figure 1 might still confuse a reader, and if the upper ones could be 
labeled as non-IPF survival and the lower ones as IPF survival curves (survival 
differences for the two cohorts per the 3 different diagnostic determination 
methods), that would make it a bit clearer for readers. 
 
Many thanks for this suggestion. We have added these labels to the graph as 
suggested.  
 
 
Statistical review comments: 
 
We would like to thank the new statistical reviewer for reviewing our manuscript 
so promptly under difficult circumstances.  
 
Major comment 1: the definition of follow up time can be further clarified, for 
example, by adding “minimum of” before the phrase “date of death, date the patient 
was last known to be alive or 1st June 2015”.  
Many thanks for this comment. We modified the manuscript accordingly.  
 
Major comment 2: no additional comment.  
 
Major comment 3: the interpretation of the reported hazard ratios should be added. 
For example, hazard ratio (IPF vs. not IPF). I don’t think the results on checking the 
PH assumptions were shown, so need to at least add a phrase “(data not shown)” in 
the description.  
Many thanks for this comment. We have added these suggestions to the 
manuscript (Methods section, statistical analysis paragraph 4).  
 
Major comment 4: no additional comment.  
 
Major comment 5: I think the requested information was provided in Table 2A, so 
this just needs to be pointed out in the response.   
The suggested detail has been reported in Table 2A. This also includes the variables 
suggested by the editors in the editorial comments (comment 5) 
 
Major comments 6 & 7: no additional comment. 
Major comment 8: suggest changing the x-axis label to be something more specific. 
For example “Time since referral (days)”. The legend seems to be incomplete. What 
lines are for the IPF and what lines are for not IPF?  
Many thanks for this suggestion. We have modified the figure accordingly and 
provided labels for the graph lines (IPF, for MDTMs, clinicians and radiologists, and 
Not-IPF, for MDTMs, cinicians and radiologists).  
Further comments: 
I find no statistical evidence presented to support the following statement “On 
univariate Cox regression analysis, MDTM diagnosis of IPF demonstrated greater 
prognostic significance than clinician’s diagnosis of IPF in 5/7 multidisciplinary 
groups, and in radiologist’s diagnosis of IPF in 4/7 groups”. What basis did the author 
use to conclude a greater prognostic significance between MDTM vs. clinicians or 
radiologists’ diagnosis? The p-value of testing HR=0? This needs to be at least 
clarified if not corrected.  
 
Many thanks for this comment 
 
The purpose for examining the prognostic separation resulting from MDTM, 
clinicians’ and radiologists’ diagnoses of IPF or not IPF was to determine whether 
major differences in prognostic separation exist. Had this been the case, routine 
multidisciplinary discussion in all cases would be justified.  The fact that trends are 
present but inconclusive may reflect powering limitations but may also indicate 
that multidisciplinary discussion adds prognostic value in the sub-group of patients 
in which there is significant diagnostic uncertainty. 
  
We agree that this statement needs clarification and actually a correction.  The 
term prognostic “significance” is confusing when what we mean is prognostic 
“separation”.  The text is modified as follows (Results, Evaluation of the prognostic 
significance of an MDTM diagnosis of IPF)  
 
 “On univariate Cox regression analysis, the multidisciplinary distinction between 
IPF and other diagnoses demonstrated greater prognostic separation (as judged by 
hazard ratio p values) than the clinician distinction (in 5/7 groups) or the 
radiologist distinction (in 4/7 groups).” 
 
We have modified the discussion (paragraph 4) as follows: 
 
“A strength of our findings is that the greater agreement on multidisciplinary 
diagnosis is mirrored by the trend toward greater prognostic separation of a 
multidisciplinary distinction between IPF and other diagnoses when compared to 
the clinicians’ or radiologists’ distinction. To demonstrate this, patients were 
necessarily selected from 2010 to allow an analysis of 5-year survival.  An added 
advantage of this approach was that these patients were referred in a pre-
antifibrotic drug era, therefore mortality differences between IPF and non-IPF 
patients were not confounded by antifibrotic therapy. The fact that trends are 
present but inconclusive may reflect powering limitations but may also indicate 
that multidisciplinary discussion adds prognostic value in the sub-group of patients 
in which there is significant diagnostic uncertainty” 
 
We have also modified the abstract by replacing the word significance with 
“separation”.  
 
The Cox regression analysis presented in Figure 1 is questionable. If I understand it 
correctly, the total diagnoses presented in the analysis were not for independent 
cases, but rather for 70 independent cases repeatedly assessed by multiple MDTMs 
or multiple individual experts. The inferences on the HRs by MDTMs in Table 4 seem 
to be appropriate because each MDTM assessed 70 independent cases.  
 
The purpose of this analysis was simply to provide a graphical demonstration of 
the greater prognostic separation of the cohort based upon MDTMs’ diagnosis (of 
IPF or not IPF) versus clinicians’ diagnosis or radiologists’ diagnosis (of IPF versus 
not IPF). I had originally graphed all 7 MDTMs, clincian’s and radiologist’s but the 
graph was very cluttered and it was difficult to visually inspect. Therefore as a 
compromise, I separated the cohort into IPF versus not IPF based upon what MOST 
of the MDTMs, clincians or radiologists diagnosed (4/7). I stress however that this 
figure was for illustrative purposes only and does not impact the message 
demonstrated by Table 4. If the reviewer has a strong view on whether this figure 
should/should not be included we would be very happy to consider that view.  
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